|

SHR-A1811 Injection Clinical Trials

3 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 3

Top Sponsors

  • Jiangsu HengRui Medicine Co., Ltd.2
  • Shengjing Hospital1

Indications

  • Cancer3
  • Recurrent or Metastatic Cervical Cancer1
  • HR Positive/HER2 Low Breast Cancer1
  • Advanced Gastric Cancer1
  • Gastroesophageal Junction Adenocarcinoma1

Other3 trials

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Phase 2
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
Phase 2
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.